Carrick Therapeutics believes in developing novel molecules to create better lives for patients. We are working on best-in-class and first-in-class therapies to complement existing treatments for several aggressive and resistant cancer types.
| Program | Cancer Indications | Stage of Development | Collaborator | ||||
|---|---|---|---|---|---|---|---|
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | |||
| Cyclin Dependent Kinase 7 (CDK7) Inhibitor | |||||||
|
HR + Her2 - mBC | ||||||
| + fulvestrant (IM SERD) |
FDA Fast Track Status
Discovery Phase complete
|
FDA Fast Track Status
Pre-Clinical Phase complete
|
FDA Fast Track Status
Phase 1 Phase complete
|
FDA Fast Track Status
Phase 2 Phase in progress
|
FDA Fast Track Status
Phase 3 Phase not started
|
|
|
| + giredestrant (oral SERD) |
Discovery Phase complete
|
Pre-Clinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
|
|
| + elacestrant (oral SERD) |
Discovery Phase complete
|
Pre-Clinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
|
|
| mCRPC anti-androgen combination | |||||||
| TNBC chemotherapy combination | FDA Fast Track Status | FDA Fast Track Status | FDA Fast Track Status | FDA Fast Track Status | FDA Fast Track Status | ||
| Pancreatic cancer chemotherapy combination |
Discovery Phase complete
|
Pre-Clinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
||
| SCLC chemotherapy combination |
Discovery Phase complete
|
Pre-Clinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
||
| Cyclin Dependent Kinase 12/13 (CDK12/13) Inhibitor / Cyclin K degrader | |||||||
|
Monotherapy: Fusion driven cancers (e.g. Ewing’s) |
Discovery Phase complete
|
Pre-Clinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
|
| PARP inhibitor combination |
Discovery Phase complete
|
Pre-Clinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
||
| Checkpoint inhibitor combination |
Discovery Phase complete
|
Pre-Clinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
||
Our lead program, samuraciclib, is a cyclin dependent kinase 7 (CDK7) inhibitor. The CDK7 target is implicated in many cancers, including breast, prostate and pancreatic cancer.
View our CDK7 inhibitor
We are developing a therapy that uses a molecule which is a dual Cyclin dependent kinase 12/13 (CDK12/13) inhibitor and Cyclin-K degrader. CDK12/13 is implicated in multiple cancer types including breast, ovarian and Ewing's Sarcoma.
View our CDK12/13 inhibitor/Cyclin-K degrader